{"id":"usual-dose-adjustment-of-enoxaparin","safety":{"commonSideEffects":[{"rate":"1-10%","effect":"Bleeding"},{"rate":"<1%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Injection site hematoma"},{"rate":"1-5%","effect":"Elevated transaminases"},{"rate":null,"effect":"Osteoporosis (with long-term use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enoxaparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of coagulation factors Xa and IIa. This prevents thrombin generation and fibrin clot formation. Dose adjustment protocols are used to optimize anticoagulation based on patient factors such as renal function, body weight, and clinical indication.","oneSentence":"Enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:18.699Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Venous thromboembolism prophylaxis"},{"name":"Acute deep vein thrombosis treatment"},{"name":"Acute pulmonary embolism treatment"},{"name":"Acute coronary syndrome (unstable angina and non-ST-segment elevation myocardial infarction)"}]},"trialDetails":[{"nctId":"NCT05672550","phase":"PHASE4","title":"Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant Recipients (OPTI-TREX)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-06-28","conditions":"Pediatric Kidney Transplant Recipients","enrollment":50},{"nctId":"NCT05848713","phase":"PHASE3","title":"AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia","status":"RECRUITING","sponsor":"University of Manitoba","startDate":"2023-10-10","conditions":"Community-acquired Pneumonia","enrollment":4000},{"nctId":"NCT04924322","phase":"PHASE2, PHASE3","title":"Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies","status":"RECRUITING","sponsor":"Yale University","startDate":"2022-05-11","conditions":"Deep Venous Thrombosis","enrollment":258},{"nctId":"NCT04372589","phase":"PHASE2, PHASE3","title":"Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)","status":"COMPLETED","sponsor":"University of Manitoba","startDate":"2020-05-20","conditions":"COVID-19, Pneumonia","enrollment":1200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Usual dose adjustment of enoxaparin","genericName":"Usual dose adjustment of enoxaparin","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Venous thromboembolism prophylaxis, Acute deep vein thrombosis treatment, Acute pulmonary embolism treatment.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}